Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2024 Jun;29(37):1–26. doi: 10.3310/GJTR5006

Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews.

Olalekan A Uthman, Lena Al-Khudairy, Chidozie Nduka, Rachel Court, Jodie Enderby, Seun Anjorin, Hema Mistry, G J Melendez-Torres, Sian Taylor-Phillips, Aileen Clarke
PMCID: PMC12434870  PMID: 38970453

Abstract

BACKGROUND

Cardiovascular diseases are the leading cause of death globally. The aim of this overview of systematic reviews was to compare the effectiveness of different pharmacological and non-pharmacological interventions for the primary prevention of cardiovascular disease.

METHODS

A structured search of the Cochrane Database of Systematic Reviews, MEDLINE, EMBASE and the Database of Abstracts of Reviews of Effects archive was conducted to find systematic reviews that reported the effect of various pharmacological and non-pharmacological interventions for the primary prevention of cardiovascular disease from inception to March 2021. References of included studies were also checked. The included systematic reviews' methodological quality was assessed using the Assessment of Multiple Systematic Reviews 2 instrument (range, 0-16). The outcomes of each included review's meta-analysis were extracted and described narratively.

RESULTS

This study analysed 95 systematic reviews, including 41 on non-pharmacological interventions and 54 on pharmacological interventions for cardiovascular health. The majority of the reviews focused on lipid-lowering interventions (n = 25) and antiplatelet medications (n = 21), followed by nutritional supplements, dietary interventions, physical activity, health promotion and other interventions. Only 1 of the 10 reviews addressing cardiovascular mortality showed a potential benefit, while the others found no effect. Antiplatelets were found to have a beneficial effect on all-cause mortality in 2 out of 12 meta-analyses and on major cardiovascular disease events in 8 out of 17 reviews. Lipid-lowering interventions showed beneficial effects on cardiovascular disease mortality, all-cause mortality and major cardiovascular disease events in varying numbers of the reviews. Glucose-lowering medications demonstrated significant benefits for major cardiovascular events, coronary heart disease events and mortality. However, the combination of dietary interventions, physical activities, nutritional supplements and polypills showed little or no significant benefit for major cardiovascular outcomes or mortality.

FUTURE WORK AND LIMITATIONS

More research is needed to determine whether the effect of treatment varies depending on population characteristics. The findings of this review should be interpreted with caution because the majority of studies of non-pharmacological interventions compare primary prevention with usual care, which may include recommended pharmacological treatment in higher-risk patients (e.g. statins and/or antihypertensive medications, etc.). In addition, randomised controlled trial evidence may be better suited to the study of pharmacological interventions than dietary and lifestyle interventions.

CONCLUSIONS

This umbrella review captured the variability in different interventions on randomised controlled trial evidence on interventions for primary prevention of cardiovascular disease and identified areas that may benefit from further research. Specifically, this review focused on randomised controlled trial evidence on interventions for primary prevention of cardiovascular disease. Researchers may use these findings as a resource to direct new intervention studies and network meta-analyses to compare the efficacy of various interventions based on these findings.

FUNDING

This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme as award number 17/148/05.

Plain language summary

Heart and blood vessel diseases are the top cause of death worldwide. This study aimed to compare the effectiveness of various drug-based and non-drug-based methods in preventing these diseases. We searched databases like Cochrane, MEDLINE, EMBASE and the Database of Abstracts of Reviews of Effects archive to find reviews about different ways to prevent heart and blood vessel diseases up until March 2021. The results showed that only 1 out of 10 reviews found a possible benefit in reducing heart-related deaths, while the other 9 found no effect. Medicines that lower blood sugar levels had a positive impact on reducing major heart events, heart disease and death. However, combining dietary changes, exercise, nutritional supplements and polypills had little or no effect on reducing heart-related events, deaths due to heart disease or deaths from all causes. This review examined the available evidence on ways to prevent heart and blood vessel diseases and identified areas where more research could be beneficial. Future studies could compare the effectiveness of different interventions using new methods and analyses.

Full text of this article can be found in Bookshelf.

References

  1. British Heart Foundation. UK Heart Disease Facts and Figures. 2022. URL: www.bhf.org.uk/what-we-do/news-from-the-bhf/contact-the-press-office/facts-and-figures#:~:text=Heart%20and%20circulatory%20diseases%20cause,men%20and%203.6%20million%20women (accessed 17 June 2022).
  2. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020;395:795–808. https://doi.org/10.1016/s0140-6736(19)32008-2 doi: 10.1016/S0140-6736(19)32008-2. [DOI] [PMC free article] [PubMed]
  3. Read SH, Wild SH. Prevention of premature cardiovascular death worldwide. Lancet 2020;395:758–60. https://doi.org/10.1016/s0140-6736(19)32034-3 doi: 10.1016/S0140-6736(19)32034-3. [DOI] [PubMed]
  4. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321–9. https://doi.org/10.1056/NEJMoa1012848 doi: 10.1056/NEJMoa1012848. [DOI] [PMC free article] [PubMed]
  5. Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC, Jr, Sanghavi DM, Brown NC, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol 2016;1:341–9. https://doi.org/10.1001/jamacardio.2016.0218 doi: 10.1001/jamacardio.2016.0218. [DOI] [PMC free article] [PubMed]
  6. Martin Ruiz E, de Labry AO, Epstein D. Primary prevention of cardiovascular disease: an umbrella review. An Sist Sanit Navar 2018;41:355–69. https://doi.org/10.23938/assn.0316 doi: 10.23938/ASSN.0316. [DOI] [PubMed]
  7. Stewart J, Addy K, Campbell S, Wilkinson P. Primary prevention of cardiovascular disease: updated review of contemporary guidance and literature. JRSM Cardiovasc Dis 2020;9:2048004020949326. https://doi.org/10.1177/2048004020949326 doi: 10.1177/2048004020949326. [DOI] [PMC free article] [PubMed]
  8. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al., ACC CVD Womens Committee Members. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2602–18. https://doi.org/10.1016/j.jacc.2020.03.060 doi: 10.1016/j.jacc.2020.03.060. [DOI] [PMC free article] [PubMed]
  9. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2019;74:1376–414. https://doi.org/10.1016/j.jacc.2019.03.009 doi: 10.1016/j.jacc.2019.03.009. [DOI] [PMC free article] [PubMed]
  10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10:89. https://doi.org/10.1186/s13643-021-01626-4 doi: 10.1186/s13643-021-01626-4. [DOI] [PMC free article] [PubMed]
  11. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. https://doi.org/10.1136/bmj.j4008 doi: 10.1136/bmj.j4008. [DOI] [PMC free article] [PubMed]
  12. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:CD003177. https://doi.org/10.1002/14651858.CD003177.pub3 doi: 10.1002/14651858.CD003177.pub3. [DOI] [PMC free article] [PubMed]
  13. Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;2014:CD009217. https://doi.org/10.1002/14651858.CD009217.pub3 doi: 10.1002/14651858.CD009217.pub3. [DOI] [PMC free article] [PubMed]
  14. Brunner E, White I, Thorogood M, Bristow A, Curle D, Marmot M. Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials. Am J Public Health 1997;87:1415–22. doi: 10.2105/ajph.87.9.1415. [DOI] [PMC free article] [PubMed]
  15. Clar C, Al-Khudairy L, Loveman E, Kelly SA, Hartley L, Flowers N, et al. Low glycaemic index diets for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;7:CD004467. https://doi.org/10.1002/14651858.CD004467.pub3 doi: 10.1002/14651858.CD004467.pub3. [DOI] [PMC free article] [PubMed]
  16. Hartley L, Igbinedion E, Holmes J, Flowers N, Thorogood M, Clarke A, et al. Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev 2013;6:CD009874. https://doi.org/10.1002/14651858.CD009874.pub2 doi: 10.1002/14651858.CD009874.pub2. [DOI] [PMC free article] [PubMed]
  17. Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2016;2016:CD011472. https://doi.org/10.1002/14651858.CD011472.pub2 doi: 10.1002/14651858.CD011472.pub2. [DOI] [PMC free article] [PubMed]
  18. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Capps NE, Smith GD, et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 2001;322:757–63. doi: 10.1136/bmj.322.7289.757. [DOI] [PMC free article] [PubMed]
  19. Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, et al. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;8:CD005051. https://doi.org/10.1002/14651858.CD005051.pub3 doi: 10.1002/14651858.CD005051.pub3. [DOI] [PMC free article] [PubMed]
  20. Martin N, Germano R, Hartley L, Adler AJ, Rees K. Nut consumption for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2015;2015:CD011583. https://doi.org/10.1002/14651858.CD011583.pub2 doi: 10.1002/14651858.CD011583.pub2. [DOI] [PMC free article] [PubMed]
  21. Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, Stranges S. ‘Mediterranean’ dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;2013:CD009825. https://doi.org/10.1002/14651858.CD009825.pub2 doi: 10.1002/14651858.CD009825.pub2. [DOI] [PubMed]
  22. Stabler SN, Tejani AM, Huynh F, Fowkes C. Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Cochrane Database Syst Rev 2012;2012:CD007653. https://doi.org/10.1002/14651858.CD007653.pub2 doi: 10.1002/14651858.CD007653.pub2. [DOI] [PMC free article] [PubMed]
  23. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013;310:2451–2. https://doi.org/10.1001/jama.2013.281348 doi: 10.1001/jama.2013.281348. [DOI] [PubMed]
  24. Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. Eur J Intern Med 2012;23:745–54. https://doi.org/10.1016/j.ejim.2012.07.004 doi: 10.1016/j.ejim.2012.07.004. [DOI] [PubMed]
  25. Angermayr L, Melchart D, Linde K. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus: a systematic review of randomized controlled trials. Ann Behav Med 2010;40:49–64. https://doi.org/10.1007/s12160-010-9206-4 doi: 10.1007/s12160-010-9206-4. [DOI] [PubMed]
  26. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011. https://doi.org/10.1002/14651858.CD001561.pub3 doi: 10.1002/14651858.CD001561.pub3. [DOI] [PMC free article] [PubMed]
  27. Merriel SWD, Andrews V, Salisbury C. Telehealth interventions for primary prevention of cardiovascular disease: a systematic review and meta-analysis. Prev Med 2014;64:88–95. https://doi.org/10.1016/j.ypmed.2014.04.001 doi: 10.1016/j.ypmed.2014.04.001. [DOI] [PubMed]
  28. Widmer RJ, Collins NM, Collins CS, West CP, Lerman LO, Lerman A. Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis. Mayo Clin Proc 2015;90:469–80. https://doi.org/10.1016/j.mayocp.2014.12.026 doi: 10.1016/j.mayocp.2014.12.026. [DOI] [PMC free article] [PubMed]
  29. Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A. Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries. Cochrane Database Syst Rev 2015;2015:CD011163. https://doi.org/10.1002/14651858.CD011163.pub2 doi: 10.1002/14651858.CD011163.pub2. [DOI] [PMC free article] [PubMed]
  30. Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper L, Rees K. Omega 6 fatty acids for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2015;2015:CD011094. https://doi.org/10.1002/14651858.CD011094.pub2 doi: 10.1002/14651858.CD011094.pub2. [DOI] [PubMed]
  31. Al-Khudairy L, Flowers N, Wheelhouse R, Ghannam O, Hartley L, Stranges S, Rees K. Vitamin C supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD011114. https://doi.org/10.1002/14651858.CD011114.pub2 doi: 10.1002/14651858.CD011114.pub2. [DOI] [PMC free article] [PubMed]
  32. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012;2012:CD007176. https://doi.org/10.1002/14651858.CD007176.pub2 doi: 10.1002/14651858.CD007176. [DOI] [PubMed]
  33. Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis. Atherosclerosis 2017;257:100–8. https://doi.org/10.1016/j.atherosclerosis.2017.01.009 doi: 10.1016/j.atherosclerosis.2017.01.009. [DOI] [PubMed]
  34. Flowers N, Hartley L, Todkill D, Stranges S, Rees K. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;2014:CD010405. https://doi.org/10.1002/14651858.CD010405.pub2 doi: 10.1002/14651858.CD010405.pub2. [DOI] [PMC free article] [PubMed]
  35. Fortmann SP, Burda BU, Senger CA, Lin J, Beil T, O’Connor E, et al. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer (structured abstract). Ann Intern Med 2013. [PubMed]
  36. Hartley L, Lee MS, Kwong JS, Flowers N, Todkill D, Ernst E, Rees K. Qigong for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2015;2015:CD010390. https://doi.org/10.1002/14651858.CD010390.pub2 doi: 10.1002/14651858.CD010390.pub2. [DOI] [PMC free article] [PubMed]
  37. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;2004:CD003177. https://doi.org/10.1002/14651858.CD003177.pub2 doi: 10.1002/14651858.CD003177.pub2. [DOI] [PMC free article] [PubMed]
  38. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013;61:440–6. https://doi.org/10.1016/j.jacc.2012.10.030 doi: 10.1016/j.jacc.2012.10.030. [DOI] [PubMed]
  39. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 2019;40:607–17. https://doi.org/10.1093/eurheartj/ehy813 doi: 10.1093/eurheartj/ehy813. [DOI] [PubMed]
  40. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, et al. Impact of different doses of omega-3 fatty acids on cardiovascular outcomes: a pairwise and network meta-analysis. Curr Atheroscler Rep 2020;22:45. https://doi.org/10.1007/s11883-020-00865-5 doi: 10.1007/s11883-020-00865-5. [DOI] [PubMed]
  41. Cabiddu MF, Russi A, Appolloni L, Mengato D, Chiumente M. Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis. Eur J Hosp Pharm 2022;29:134–8. https://doi.org/10.1136/ejhpharm-2020-002207 doi: 10.1136/ejhpharm-2020-002207. [DOI] [PMC free article] [PubMed]
  42. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, Park BJ, Korean Meta-Analysis Study Group. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013;346:f10. https://doi.org/10.1136/bmj.f10 doi: 10.1136/bmj.f10. [DOI] [PMC free article] [PubMed]
  43. Pham DQ, Plakogiannis R. Vitamin E supplementation in cardiovascular disease and cancer prevention: part 1. Ann Pharmacother 2005;39:1870–8. https://doi.org/10.1345/aph.1G211 doi: 10.1345/aph.1G211. [DOI] [PubMed]
  44. Qin X, Huo Y, Xie D, Hou F, Xu X, Wang X. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr 2013;32:722–7. https://doi.org/10.1016/j.clnu.2012.12.009 doi: 10.1016/j.clnu.2012.12.009. [DOI] [PubMed]
  45. Rees K, Hartley L, Day C, Flowers N, Clarke A, Stranges S. Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;2013:CD009671. https://doi.org/10.1002/14651858.CD009671.pub2 doi: 10.1002/14651858.CD009671.pub2. [DOI] [PMC free article] [PubMed]
  46. Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev 2017;6:CD009744. https://doi.org/10.1002/14651858.CD009744.pub2 doi: 10.1002/14651858.CD009744.pub2. [DOI] [PMC free article] [PubMed]
  47. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315–23. https://doi.org/10.7326/0003-4819-152-5-201003020-00010 doi: 10.7326/0003-4819-152-5-201003020-00010. [DOI] [PubMed]
  48. Yang L, Ling W, Du Z, Chen Y, Li D, Deng S, et al. Effects of anthocyanins on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2017;8:684–93. https://doi.org/10.3945/an.116.014852 doi: 10.3945/an.116.014852. [DOI] [PMC free article] [PubMed]
  49. Ramôa Castro A, Oliveira NL, Ribeiro F, Oliveira J. Impact of educational interventions on primary prevention of cardiovascular disease: a systematic review with a focus on physical activity. Eur J Gen Pract 2017;23:59–68. https://doi.org/10.1080/13814788.2017.1284791 doi: 10.1080/13814788.2017.1284791. [DOI] [PMC free article] [PubMed]
  50. Hartley L, Dyakova M, Holmes J, Clarke A, Lee MS, Ernst E, Rees K. Yoga for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;2014:CD010072. https://doi.org/10.1002/14651858.CD010072.pub2 doi: 10.1002/14651858.CD010072.pub2. [DOI] [PMC free article] [PubMed]
  51. Hartley L, Flowers N, Lee MS, Ernst E, Rees K. Tai chi for primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;4:CD010366. https://doi.org/10.1002/14651858.CD010366.pub2 doi: 10.1002/14651858.CD010366.pub2. [DOI] [PMC free article] [PubMed]
  52. Reed JL, Prince SA, Elliott CG, Mullen KA, Tulloch HE, Hiremath S, et al. Impact of workplace physical activity interventions on physical activity and cardiometabolic health among working-age women: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017;10:e003516. https://doi.org/10.1161/CIRCOUTCOMES.116.003516 doi: 10.1161/CIRCOUTCOMES.116.003516. [DOI] [PubMed]
  53. Antithrombotic Trialists Collaborators. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [Erratum appears in BMJ 2002;324(7330):141]. BMJ 2002;324:71–86. doi: 10.1136/bmj.324.7329.71. [DOI] [PMC free article] [PubMed]
  54. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796–801. https://doi.org/10.1016/j.amjcard.2011.02.325 doi: 10.1016/j.amjcard.2011.02.325. [DOI] [PubMed]
  55. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–13. https://doi.org/10.1001/jama.295.3.306 doi: 10.1001/jama.295.3.306. [DOI] [PubMed]
  56. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300–6. https://doi.org/10.2337/dc09-1297 doi: 10.2337/dc09-1297. [DOI] [PMC free article] [PubMed]
  57. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018–24. https://doi.org/10.1001/jama.297.18.2018 doi: 10.1001/jama.297.18.2018. [DOI] [PubMed]
  58. Caldeira D, Alves M, David C, Costa J, Ferreira JJ, Pinto FJ. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis. Prim Care Diabetes 2020;14:213–21. https://doi.org/10.1016/j.pcd.2019.11.004 doi: 10.1016/j.pcd.2019.11.004. [DOI] [PubMed]
  59. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. https://doi.org/10.1136/bmj.b4531 doi: 10.1136/bmj.b4531. [DOI] [PMC free article] [PubMed]
  60. Desai D, Ahmed HM, Michos ED. Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Curr Cardiol Rep 2015;17:566. https://doi.org/10.1007/s11886-015-0566-z doi: 10.1007/s11886-015-0566-z. [DOI] [PubMed]
  61. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006–10. https://doi.org/10.1001/archinte.163.17.2006 doi: 10.1001/archinte.163.17.2006. [DOI] [PubMed]
  62. Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med 2019;17:198. https://doi.org/10.1186/s12916-019-1428-0 doi: 10.1186/s12916-019-1428-0. [DOI] [PMC free article] [PubMed]
  63. Masson G, Lobo M, Masson W, Molinero G. Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. Arch Cardiol Mex 2020;90:293–9. https://doi.org/10.24875/acm.20000267 doi: 10.24875/ACM.20000267. [DOI] [PubMed]
  64. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57:326–32. doi: 10.1001/archneur.57.3.326. [DOI] [PubMed]
  65. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. [Summary for patients in Ann Intern Med. 2002 Jan 15;136(2):I55;PMID: 11928737]. Ann Intern Med 2002;136:161–72. doi: 10.7326/0003-4819-136-2-200201150-00016. [DOI] [PubMed]
  66. Nudy M, Cooper J, Ghahramani M, Ruzieh M, Mandrola J, Foy AJ. Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: a meta-regression analysis. Am J Med 2020;133:1056–64. https://doi.org/10.1016/j.amjmed.2020.04.028 doi: 10.1016/j.amjmed.2020.04.028. [DOI] [PubMed]
  67. Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621–9. https://doi.org/10.1016/j.amjmed.2011.01.018 doi: 10.1016/j.amjmed.2011.01.018. [DOI] [PubMed]
  68. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265–71. doi: 10.1136/heart.85.3.265. [DOI] [PMC free article] [PubMed]
  69. Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci 2011;341:1–9. https://doi.org/10.1097/MAJ.0b013e3181f1fba8 doi: 10.1097/MAJ.0b013e3181f1fba8. [DOI] [PubMed]
  70. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLOS ONE 2013;8:e81970. https://doi.org/10.1371/journal.pone.0081970 doi: 10.1371/journal.pone.0081970. [DOI] [PMC free article] [PubMed]
  71. Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. PLOS ONE 2014;9:e90286. https://doi.org/10.1371/journal.pone.0090286 doi: 10.1371/journal.pone.0090286. [DOI] [PMC free article] [PubMed]
  72. Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010;11:1459–66. https://doi.org/10.1517/14656561003792538 doi: 10.1517/14656561003792538. [DOI] [PubMed]
  73. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;87:211–8. https://doi.org/10.1016/j.diabres.2009.09.029 doi: 10.1016/j.diabres.2009.09.029. [DOI] [PubMed]
  74. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2015;387:957–67. https://doi.org/10.1016/s0140-6736(15)01225-8 doi: 10.1016/S0140-6736(15)01225-8. [DOI] [PubMed]
  75. Fretheim A, Odgaard-Jensen J, Brørs O, Madsen S, Njølstad I, Norheim OF, et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med 2012;10:33. https://doi.org/10.1186/1741-7015-10-33 doi: 10.1186/1741-7015-10-33. [DOI] [PMC free article] [PubMed]
  76. Wei CY, Quek RGW, Villa G, Gandra SR, Forbes CA, Ryder S, et al. A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies. PharmacoEconomics 2017;35:297–318. https://doi.org/10.1007/s40273-016-0464-2 doi: 10.1007/s40273-016-0464-2. [DOI] [PubMed]
  77. Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine 2019;98:e18245. https://doi.org/10.1097/md.0000000000018245 doi: 10.1097/MD.0000000000018245. [DOI] [PMC free article] [PubMed]
  78. Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, Esposito K. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract 2020;162:108114. https://doi.org/10.1016/j.diabres.2020.108114 doi: 10.1016/j.diabres.2020.108114. [DOI] [PubMed]
  79. Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol 2020;8:418–35. https://doi.org/10.1016/s2213-8587(20)30038-3 doi: 10.1016/S2213-8587(20)30038-3. [DOI] [PubMed]
  80. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin 2006;22:617–23. https://doi.org/10.1185/030079906X89865 doi: 10.1185/030079906X89865. [DOI] [PubMed]
  81. Das A, Roy B, Bandyopadhyay D, Dasgupta S, Chakraborty S, Soudant C, et al. Non-statin interventions in the prevention of cardiovascular events: sex-based meta-analysis. Prog Cardiovasc Dis 2020;63:228–32. https://doi.org/10.1016/j.pcad.2020.03.012 doi: 10.1016/j.pcad.2020.03.012. [DOI] [PubMed]
  82. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020;396:1637–43. https://doi.org/10.1016/s0140-6736(20)32332-1 doi: 10.1016/S0140-6736(20)32332-1. [DOI] [PMC free article] [PubMed]
  83. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011;162:115–24.e2. https://doi.org/10.1016/j.ahj.2011.04.006 doi: 10.1016/j.ahj.2011.04.006. [DOI] [PubMed]
  84. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol 2010;13:84–90. https://doi.org/10.1111/j.1751-7141.2009.00059.x doi: 10.1111/j.1751-7141.2009.00059.x. [DOI] [PubMed]
  85. Chang YH, Hsieh MC, Wang CY, Lin KC, Lee YJ. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients – a systematic review and meta-analysis. Rev Diabet Stud 2013;10:157–70. https://doi.org/10.1900/rds.2013.10.157 doi: 10.1900/RDS.2013.10.157. [DOI] [PMC free article] [PubMed]
  86. Chen YH, Feng B, Chen ZW. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes 2012;120:116–20. https://doi.org/10.1055/s-0031-1297968 doi: 10.1055/s-0031-1297968. [DOI] [PubMed]
  87. Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates – a pooled meta-analysis. Am J Ther 2010;17:e182–8. https://doi.org/10.1097/MJT.0b013e3181dcf72b doi: 10.1097/MJT.0b013e3181dcf72b. [DOI] [PubMed]
  88. Major RW, Cheung CK, Gray LJ, Brunskill NJ. Statins and cardiovascular primary prevention in CKD: a meta-analysis. Clin J Am Soc Nephrol 2015;10:732–9. https://doi.org/10.2215/CJN.07460714 doi: 10.2215/CJN.07460714. [DOI] [PMC free article] [PubMed]
  89. Marti-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017;8:CD006612. https://doi.org/10.1002/14651858.CD006612.pub5 doi: 10.1002/14651858.CD006612.pub5. [DOI] [PMC free article] [PubMed]
  90. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769–81. https://doi.org/10.1016/j.jacc.2008.08.039 doi: 10.1016/j.jacc.2008.08.039. [DOI] [PubMed]
  91. Mills EJ, O’Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40 000 patients. Eur Heart J 2011;32:1409–15. https://doi.org/10.1093/eurheartj/ehr035 doi: 10.1093/eurheartj/ehr035. [DOI] [PubMed]
  92. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–77. https://doi.org/10.1161/CIRCULATIONAHA.109.906479 doi: 10.1161/CIRCULATIONAHA.109.906479. [DOI] [PMC free article] [PubMed]
  93. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983–6. doi: 10.1136/bmj.321.7267.983. [DOI] [PMC free article] [PubMed]
  94. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943–53. https://doi.org/10.1016/j.ahj.2007.07.011 doi: 10.1016/j.ahj.2007.07.011. [DOI] [PubMed]
  95. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010;141:157–66. https://doi.org/10.1016/j.ijcard.2008.11.211 doi: 10.1016/j.ijcard.2008.11.211. [DOI] [PubMed]
  96. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013. https://doi.org/10.1002/14651858.cd004816.pub5 doi: 10.1002/14651858.CD004816.pub5. [DOI] [PMC free article] [PubMed]
  97. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011;24:843–53. https://doi.org/10.1038/ajh.2011.115 doi: 10.1038/ajh.2011.115. [DOI] [PubMed]
  98. Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging 2015;32:649–61. https://doi.org/10.1007/s40266-015-0290-9 doi: 10.1007/s40266-015-0290-9. [DOI] [PubMed]
  99. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307–13. https://doi.org/10.1001/archinte.166.21.2307 doi: 10.1001/archinte.166.21.2307. [DOI] [PubMed]
  100. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al.; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011;183:E1189–202. https://doi.org/10.1503/cmaj.101280 doi: 10.1503/cmaj.101280. [DOI] [PMC free article] [PubMed]
  101. Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med 1999;14:763–74. doi: 10.1046/j.1525-1497.1999.02109.x. [DOI] [PMC free article] [PubMed]
  102. de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLOS ONE 2014;9:e111247. https://doi.org/10.1371/journal.pone.0111247 doi: 10.1371/journal.pone.0111247. [DOI] [PMC free article] [PubMed]
  103. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012;72:2365–73. https://doi.org/10.2165/11638240-000000000-00000 doi: 10.2165/11638240-000000000-00000. [DOI] [PubMed]
  104. Sepanlou SG, Farzadfar F, Jafari E, Danaei G. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation. Arch Iran Med 2012;15:531–7. https://doi.org/012159/AIM.004 [PubMed]
  105. de Cates AN, Farr MRB, Wright N, Jarvis MC, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;4:CD009868. https://doi.org/10.1002/14651858.CD009868.pub2 doi: 10.1002/14651858.CD009868.pub2. [DOI] [PMC free article] [PubMed]
  106. Hartley L, Mavrodaris A, Flowers N, Ernst E, Rees K. Transcendental meditation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;2017:CD010359. https://doi.org/10.1002/14651858.CD010359.pub3 doi: 10.1002/14651858.CD010359.pub2. [DOI] [PubMed]

RESOURCES